Publication Name	World Journal of Gastroenterology
Manuscript ID	12408
Country	Singapore

Received	2014-07-07 18:03
Peer-Review Started	2014-07-08 14:09
To Make the First Decision	2014-08-06 17:21
Return for Revision	2014-08-08 14:52
Revised	2014-08-20 14:21
Second Decision	2014-10-15 07:39
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2014-10-15 08:12
Articles in Press	2014-10-15 08:26
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2014-12-22 14:42
Publish the Manuscript Online	2015-01-07 11:07

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access
Copyright
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Oncology
Manuscript Type	Review
Article Title	p53 mutations in colorectal cancer- molecular pathogenesis and pharmacological reactivation
Manuscript Source	Unsolicited Manuscript
All Author List	Xiao-Lan Li, Jianbiao Zhou, Zhi-Rong Chen and Wee-Joo Chng
Funding Agency and Grant Number	Funding Agency Grant Number National Research Foundation Singapore and the Singapore Ministry of Education under its Research Centres of Excellence initiative NMRC Clinician-Scientist IRG Grant CNIG11nov38 (Zhou J) NMRC Clinician Scientist Investigator award to Chng WJ
Corresponding Author	Wee-Joo Chng, MD, PhD, Associate Professor, Department of Hematology-Oncology, National University Hospital, 1E, Kent Ridge Road, Singapore 119228, Singapore. mdccwj@nus.edu.sg
Key Words	Colorectal cancer; p53; Tumor suppressor; Small molecule inhibitor; Gene therapy; PRIMA-1MET
Core Tip	Dysregulation of p53 tumor suppressor gene is one of the most frequent events contributing to the transformation of colorectal cancer (CRC), as well as the aggressive and metastatic features of CRC. Mutant p53 reactivator, PRIMA-1MET has been tested in Phase Ⅰ/Ⅱ clinical trials and shows encouraging benefits. In this review, we systemically and comprehensively summarize the current understanding of p53 mutations in the pathogenesis of CRC and current progress in reactivation of p53 as a novel therapeutic strategy. We hope this review will promote more investigations of reactivation of p53 as a viable treatment option of patients with CRC.
Publish Date	2015-01-07 11:07
Citation	Li XL, Zhou J, Chen ZR, Chng WJ. p53 mutations in colorectal cancer- molecular pathogenesis and pharmacological reactivation. World J Gastroenterol 2015; 21(1): 84-93
URL	http://www.wjgnet.com/1007-9327/full/v21/i1/84.htm
DOI	http://dx.doi.org/10.3748/wjg.v21.i1.84

Full Article (PDF)	WJG-21-84.pdf
Full Article (Word)	WJG-21-84.doc
Manuscript File	12408-Review.doc
Answering Reviewers	12408-Answering reviewers.pdf
Copyright License Agreement	12408-Copyright assignment.pdf
Peer-review Report	12408-Peer review(s).pdf
Scientific Misconduct Check	12408-CrossCheck.jpg
Scientific Editor Work List	12408-Scientific editor work list.pdf